Loading...
Market
Will CAN-2409 receive FDA approval for prostate cancer by end of 2025?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
FDA official announcements and press releases
Story
Candel Therapeutics' CAN-2409 Succeeds in Phase 3 Prostate Cancer Trial, Shares Soar
Dec 11, 2024, 12:48 PM
Candel Therapeutics announced that its experimental immunotherapy, CAN-2409, met the primary endpoint in a Phase 3 trial for prostate cancer, showing significantly improved disease-free survival. Following the announcement, the company's shares more than doubled in value in premarket trading. CAN-2409 is an oncolytic virus designed to stimulate the immune system to attack cancer cells. The trial's success marks a significant milestone for Candel Therapeutics, potentially paving the way for further development and regulatory approval of the treatment.
View original story
Similar markets
Yes • 50%
No • 50%
Mesothelioma • 25%
Lung Cancer • 25%
Breast Cancer • 25%
Other • 25%